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Background. Information leaflets have been shown to positively or negatively impact adherence, depending on their content. The
objective of this study was to perform an appraisal of the consumer information provided in COPD inhaler monographs.Methods.
COPD inhalers were identified from the Health Canada Drug Product Database. Medication information and instructions for
inhaler use were analyzed for readability by seven formulas, with an acceptability threshold of grades 6–8. Three researchers rated
suitability using a modified Suitability Assessment of Materials (SAM) tool and assessed leaflets for explicit warnings. Results.
Twenty-six inhalers with a COPD indication were evaluated. Medication information sections were rated as “difficult to read” or
“hard,” and 85% (22/26) had a reading level above grade 8. The instructions for inhaler use were rated as “easy” or “fairly easy” to
read and 63% (16/26) met the threshold by all formulas. While all leaflets achieved superior suitability ratings, extreme warnings
included risk of premature death (𝑛 = 12), risks of serious injury (𝑛 = 26), serious interactions (𝑛 = 26), and statements that
convey a serious consequence to therapy (𝑛 = 26). Conclusion. While COPD information leaflets in Canada performed well in
terms of readability and suitability, overemphasis on side effects, warnings, and precautions may contribute to patient fear and
nonadherence.
1. Background
Information leaflets are considered an important facet of
patient education for all types of prescriptionmedications [1].
In the case of inhaled agents for COPD, printed information
not only serves to provide basic education about the drug but
also contains detailed instructions about proper technique for
administration. Indeed, administration of inhalers requires
a certain degree of technical competence and suboptimal
technique has been associated with an increased risk of
hospitalizations, along with increased use of antibiotics and
corticosteroids [2, 3].
In Canada alone, at least $1.5 billion dollars are spent on
COPD hospitalizations annually [4], and COPD is the 4th
leading cause of death in Canada and the only major chronic
health condition wheremortality rates are actually increasing
[4, 5]. Although many medications were shown to reduce
the risk of hospitalization [6], their use is clearly suboptimal.
An average of 60% of patients with COPD do not adhere
to prescribed therapy and up to 85% of patients use their
inhalers ineffectively [7].
Patient information leaflets have the ability to positively
enhance medication knowledge, patient satisfaction, and
medication adherence [8]. On the other hand, poorly pre-
sented information in monographs can lead to misinterpre-
tations of adverse effects and nonadherence to the prescribed
therapy [9, 10]. Guidelines have been suggested on how to
write patient friendly information appropriate for the general
public [11]. Nevertheless, the readability of these materials
often exceeds the recommended grade level [12]. Moreover,
information leaflets have frequently been criticized for their
potential to increase patient fears over drug safety [10].
The purpose of this study was to conduct an appraisal of
the quality of information provided in the product mono-
graphs of COPD inhalers available in Canada.
2. Methods
2.1. COPD Inhalation Devices Identification. A search was
conducted to identify all inhaled medications marketed in
Canada for COPD using the national Drug Product Database
[13]. Search termswere selectedwithin each field of the online
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Table 1: Readability interpretation.
(i) Flesch Reading Ease (i) Gunning Fog
(i) Flesch-Kincaid Grade Level
(ii) Coleman-Liau Index
(iii) SMOG Index
(iv) Automated Readability Index
(v) Linsear Write Formula
90–100: very easy
5: readable
10: hard
15: difficult
20: very difficult
Number is considered equivalent
to grade level. Anything above 12
is considered college level.
80–89: easy
70–79: fairly easy
60–69: standard
50–59: fairly difficult
30–49: difficult
0–29: very confusing
SMOG: simple measure of Gobbledygook.
database as follows: Status: “marketed and approved”; (i)
Class(es): “human”; (ii) Route(s) of administration: “inhala-
tion”; (iii) Dosage form(s): “all”; and (iv) Schedules: “pre-
scription”. Monographs were reviewed to identify devices
specifically indicated for the treatment of COPD. Nebulized
products were excluded.
For each product monograph identified, the consumer
information section written in English (i.e., Part 3) was
assessed for readability and suitability. In addition, a subjec-
tive assessment was undertaken to identify potential mes-
sages that might exaggerate the perception of risk associated
with regular use.
2.2. Readability. While there are a variety of methods used
to assess the readability of written materials, there is no con-
sensus as to which formula is best suited for assessing patient
education materials. To improve the validity of the results, it
is favourable to use a variety of methods [14]. As such the
readability of each leaflet was assessed with seven formulas:
the Flesch Reading Ease formula [15], the Flesch-Kincaid
Grade Level readability formula [16], the Gunning Fog Index
[17], the SMOG Index [18], the Automated Readability Index
[19], the Coleman-Liau Index [20], and the Linsear Write
Formula [21]. These formulas use average sentence length,
number of syllables, or average word length to calculate a
reading ease or a reading grade level (Table 1). It is suggested
that health information should be written no higher than
grades 6–8 reading level to accommodate patients with poor
health literacy [11].
Consumer information in eachmonographwas separated
into “medication information” and “instructions on inhaler
use.” Each of these sections was entered separately into
an online readability calculator [22]. Sections pertaining to
reporting side effects to Health Canada and supplemental
information were excluded.
2.3. Suitability. A suitability assessment was conducted on
the leaflets to evaluate additional factors that may impact
health literacy [11]. Two different researchers independently
assessed each document using a modified version of the
Suitability Assessment of Materials (SAM) tool [23, 24]. A
third researcher was used to make a final decision in the
event of a discrepancy.Themodified SAM tool consisted of 16
items after removal of irrelevant elements (“cultural appropri-
ateness”, “summary reviews”, “cover graphics”, “lists/tables”,
and “interaction used”) (Table 2). The Flesch-Kincaid Grade
Level formula [16] was used to assess item (2)(a): Reading
Grade Level.
Each factor was given a rating of “superior,” “adequate,”
or “not suitable,” which has a value of 2, 1, or 0, respectively
[11, 23].The values for each inhaler were summed and divided
by themaximumscore of 32 to produce a percentage.Theper-
centages were categorized as 70–100% (“superior” material),
40–69% (“adequate” material), and 0–39% (“not suitable”
material) [11, 23].
2.4. Medication Risks. Finally, a subjective review of each
monograph was conducted to identify messages that ap-
peared to exaggerate the risk posed to patients.Messageswere
categorized as highlighting (a) risks of premature death; (b)
risks of serious injury; (c) risks of serious interactions; (d)
statements that convey a serious consequence to therapy.
3. Results
One hundred and fifty-one medications met the search
criteria on the Drug Product Database. After excluding the
nebulized medications (𝑛 = 40), 26 inhalers were found to
have aCOPD indication andwere assessed for readability and
suitability (Table 3). Of these, 22 were branded products and
four were produced by generic companies.
3.1. Readability. Readability of the medication information
sections from each of the 26 leaflets was rated as “fairly
difficult,” “difficult,” or “hard.” None of themonographs were
assessed within the recommended grade level of 6–8 by all
formulas, and only 26% (7/26) met the target by at least one
method (Table 4). In contrast, sections relating to inhaler use
instructions were rated as “easy” or “fairly easy” to read and
the most complex monographs were rated as “average.” The
majority of the instructions for inhaler use (77%, 20/26) met
the target grade level of 6–8 by all formulas. (Table 5).
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Table 2: Modified Suitability Assessment.
Category Element
(1) Content
(a) Purpose (the purpose is evident)
(b) Content topics (suggests behaviors that will help solve a problem)
(c) Scope (scope is limited to the purpose of objective)
(2) Literacy demand
(a) Reading grade level (reading grade level score)
(b) Writing style (text is written in a conversational style and active voice)
(c) Vocabulary (vocabulary uses common words)
(d) Sentence construction (context is given first)
(e) Advanced organizers (advanced organizers are used to tell what is next)
(3) Graphics
(a) Type of illustrations (graphics are appropriate for the communication)
(b) Relevance of illustrations (illustrations provide key ideas and messages)
(c) Graphic captions (graphics have a corresponding caption)
(4) Layout and type
(a) Layout (layout factors)
(b) Typography (font size and style)
(c) Subheading (subheadings are used)
(5) Learning stimulation and motivation (a) Behavior (behaviors are modeled and specific)
(b) Motivation (actions are achievable promoting self-efficacy)
Table 3
Inhaler Type Manufacturer
Advair Diskus DPI GlaxoSmithKline
Airomir∗ MDI Valeant Canada LP
Anoro Ellipta DPI GlaxoSmithKline
Apo-Salvent CFC Free∗ MDI Apotex
Atrovent HFA MDI Boehringer Ingelheim
Breo Elliptaa DPI GlaxoSmithKline
Bricanyl Turbuhaler DPI AstraZeneca
Combivent Respimat SMI Boehringer Ingelheim
Duaklir Genuair DPI AstraZeneca
Foradil Aerolizer DPI Novartis Pharmaceuticals
Incruse Ellipta DPI GlaxoSmithKline
Inspiolto Respimat SMI Boehringer Ingelheim
Novo-Salbutamol HFA∗ MDI Teva Canada
Onbrez Breezhaler DPI Novartis Pharmaceuticals
Salbutamol HFA∗ MDI Sanis Health
Seebri Breezhaler DPI Novartis Pharmaceuticals
Serevent Diskhaler Disk DPI GlaxoSmithKline
Serevent Diskus DPI GlaxoSmithKline
Spiriva DPI (handihaler) Boehringer Ingelheim
Spiriva Respimat SMI Boehringer Ingelheim
Striverdi Respimatb SMI Boehringer Ingelheim
Symbicort Turbuhalerb DPI AstraZeneca
Tudorza Genuair DPI AstraZeneca
Ultibro Breezhaler DPI Novartis Pharmaceuticals
Ventolin Diskus DPI GlaxoSmithKline
Ventolin HFA HFA GlaxoSmithKline
∗Generic products; aonly 100/25mcg/dose indicated in COPD; bapproved by Health Canada but not currently marketed; MDI: metered dose inhaler; DPI: dry
powdered inhaler; SMI: soft mist inhaler.
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Table 4: Readability of patient medication information.
Inhaler Flesch ReadingEase Gunning Fog
Flesch-Kincaid
Grade Level
Coleman-Liau
Index SMOG Index
Automated
Readability Index
Linsear Write
Formula
Advair Diskus 58.9 11.2 8.5 11 8.3 8.4 8
Airomir 44.8 14.2 12.5 11 12 12.5 15.4
Anoro Ellipta 54.1 11 9.6 10 9.6 8.7 10.6
Apo-Salvent CFC Free 48.8 14.1 12.2 10 10.7 12.4 15
Atrovent HFA 42.6 15.6 12.8 12 11.8 13.4 15.1
Breo Ellipta 55.9 11.8 10 10 9.5 10.1 11.8
Bricanyl Turbuhaler 44.3 13.5 11.8 13 10.8 12.3 12.9
Combivent Respimat 30.6 17.3 14.9 14 13.5 15.6 17.3
Duaklir Genuair 35.5 15.7 13.9 13 12.9 14.5 16.2
Foradil Aerolizer 46.4 13 10.8 12 10.2 10.5 11.1
Incruse Ellipta 58.2 10.7 8.9 10 8.6 8.4 8.7
Inspiolto Respimat 33.1 15.4 13.9 13 12.5 14.2 15.3
Novo-Salbutamol HFA 45.2 13.7 12.1 11 11 12.2 13.8
Onbrez Breezhaler 51.3 11.7 10.1 13 8.8 11 9.4
Salbutamol HFA 50 13.2 11.4 11 10.5 11.6 13.7
Seebri Breezhaler 49.1 12.5 11 12 9.1 11.9 11.6
Serevent Diskhaler Disk 58.7 10.7 8.5 11 8.4 8.7 8
Serevent Diskus 58.1 10.9 8.6 11 8.5 8.4 8.1
Spiriva 46.5 13.4 11.5 12 10.9 11.8 13.1
Spiriva Respimat 42.3 14.2 12.4 12 11.6 12.5 14.1
Striverdi Respimat 41.1 13.9 12.3 13 11.7 12.9 13.6
Symbicort 58.9 9.8 8.6 10 8.6 8.1 8.3
Tudorza Genuair 47.5 13.5 11 12 10.8 11 12.3
Ultibro Breezhaler 45.6 12.7 11.4 13 10.1 12.1 12.1
Ventolin Diskus 45.1 14.3 12.9 11 11.2 13.7 15.7
Ventolin HFA 51.4 13.2 11.3 10 10.5 11.5 13.7
3.2. Suitability. All patient information documents achieved
a “superior” rating in the categories of purpose, content
topics, scope, sentence construction, and behaviors but were
deemed “not suitable” for their suboptimal reading grade
level.The number of graphics in each leaflet ranged from 3 to
14, with a mean number of 8.5. Nevertheless, all documents
received “superior” ratings for containing applicable infor-
mation on what the medication was for and how to use the
devices.
3.3. Medication Safety. None of the monographs contained
a section dedicated to the benefits of the medication but all
contained explicit information on potential risks. Twelve of
the 26 inhalers (46%) contained a highlighted warning about
the risk of asthma-related deaths associated with the use of
the product (i.e., all products containing long-acting beta-
2 agonists). All products (26/26) contained risks of serious
injury, serious interactions, and statements that convey a
serious consequence to therapy. For instance, warnings about
dizziness or blurred vision were frequently present and
included cautions about driving or operating machinery
(𝑛 = 11). All leaflets had warnings on excessive use, using
strong language such as “extremely dangerous,” or to “contact
a health care provider immediately if you think you have
taken too much.” A statement indicating that “the safety and
effectiveness in children under the age of 4 years is not known”
was found on all salbutamol inhalers (𝑛 = 6) (and in one
leaflet the “safe age” was listed at 6). Some of the warnings are
not supported in the literature, such as advising consumers to
avoid contact with anyone withmeasles or the chickenpox, in
the case of inhaled corticosteroids (𝑛 = 3).
In general, warnings, precautions, and drug interactions
were amajor focus of the information provided for each prod-
uct, often taking up the majority of the space in the leaflet.
4. Discussion
The provision of patient education is a critical factor for the
success of inhaler medications in patients with COPD [25].
Although written information is no substitute for face-to-
face education, it has an undeniable influence on the use
and perceptions of medications [25]. Health Canada man-
dates that drug manufacturers develop a detailed consumer
information leaflet to educate patients on each medication’s
purpose, proper administration, and potential side effects
[26]. The document should be written using the “simplest,
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Table 5: Readability of inhaler use instructions.
Inhaler Flesch Reading
Ease Gunning Fog
Flesch-Kincaid
Grade Level
Coleman-Liau
Index SMOG Index
Automated
Readability Index
Linsear Write
Formula
Advair Diskus 81.6 6.1 4.2 7 4.6 3.2 4.3
Airomir 80.8 7.5 5.4 7 6.2 5.2 6.9
Anoro Ellipta 74.3 7.3 5.5 7 6.7 3.9 5.6
Apo-Salvent CFC Free 81.2 7.6 5.4 7 5.9 5.2 7
Atrovent HFA 66.8 10.7 7.4 9 8.4 7 8
Breo Ellipta 77.8 7.5 5 7 6.5 3.5 5.5
Bricanyl Turbuhaler 74.8 8.6 6.4 7 7 5.9 7.5
Combivent Respimat 80.3 6.8 4.8 7 5.9 3.8 5.6
Duaklir Genuair 65.8 9.8 8.3 9 8.4 8.7 10.5
Foradil Aerolizer 79 7.1 4.7 8 5.4 4.4 4.8
Incruse Ellipta 74.9 7.5 5.5 7 6.8 3.9 5.6
Inspiolto Respimat 79.4 6.8 5 7 5.8 3.8 5.5
Novo-Salbutamol HFA 71.7 9.8 6.6 8 7.5 6 7.4
Onbrez Breezhaler 69.8 7.2 6.2 10 5.8 6.3 5.4
Salbutamol HFA 72.8 8.8 6.2 9 6.9 5.8 6.6
Seebri Breezhaler 73.6 6.7 5.5 9 5.1 5.4 4.7
Serevent Diskhaler Disk 81.2 6.5 4.8 8 4.9 4.8 5.4
Serevent Diskus 82.6 5.7 4 7 4.4 2.8 4
Spiriva Handihaler 79.9 5.7 4.4 8 5.3 4 4.4
Spiriva Respimat 80.4 6.7 4.8 7 5.8 3.6 5.5
Striverdi Respimat 81.2 6.5 4.6 7 5.7 3.6 5.2
Symbicort 82.5 6.9 4.3 6 5.7 3 5
Tudorza Genuair 64.1 10.3 8.6 10 9 9.1 11
Ultibro Breezhaler 71.1 6.7 5.7 10 5.8 5.5 4.9
Ventolin Diskus 80.4 5.8 4.6 7 5.6 3.5 5
Ventolin HFA 73.8 8.8 6.1 8 6.9 5.7 6.6
shortest words possible,” using a language and format that is
appropriate for the general public [27].
In general, COPD inhaler monographs contained highly
readable instructions for use while more complex language
was found in their patient information sections. Achieving
an acceptable reading level is important, since approximately
60% of Canadians over age 16 have a low level of health
literacy and lack the necessary skills to properly manage their
health independently [28]. Poor health literacy in COPD is
associated with increased disease severity, frequent hospital-
izations, and a decrease in quality of life [29]. Low education
levels are also a predictor of poor or incorrect inhaler
technique [3, 30]. Improved outcomes in COPD will not
be achievable if patients cannot understand how to use the
devices. Althoughwe find it encouraging that the instructions
for inhaler use were generally rated as acceptable, there is cer-
tainly room for improvementwith respect to patient informa-
tion.
The suitability of COPD inhaler monographs was rated
as “superior” for the applicability of information and how
to use the devices. Nevertheless, all of the leaflets dedicated
substantial space to the issue of medication safety, including
explicit warnings about the risk of premature death. In
many cases, more space was dedicated to warnings than
correct administration technique. Not one of the leaflets we
analyzed had a section dedicated to benefits. Including such
information is arguably as important [31], since patients often
do not recall all of the information provided by their health
care provider regarding the rationale for use [32].
It has previously been suggested that written sources of
drug information “seem designedmore to satisfy [governments
and liability lawyers than] to teach patients. . .” [33]. In our
study, all monographs for inhalers containing long-acting
beta-agonists (𝑛 = 12) warned about a risk of premature
death. A recent systematic review of randomized studies in
adult asthma patients found 46 deaths in 17,572 patients rand-
omized to salmeterol or formoterol (0.26%) compared to 33
deaths in 16,380 patients randomized to control (0.20%) for
a pooled OR of 1.37 (95% CI: 0.88 to 2.13) [34]. Although it
must be acknowledged that signals of risk need to be clearly
communicated to patients, the tone and severity of themono-
graphs examined in this study far exceeded the objective risks
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identified in clinical trials [34]. Furthermore, in the treatment
of COPD, LABAs used asmonotherapy are recognized as safe
and effective therapeutic options [6].
Several other examples of excessive warnings were dis-
covered as well. Despite the fact that inhaled short-acting
beta-agonists are widely used as first-line therapy for the
treatment of bronchospasm in pediatric patients [35, 36], one
of the first warnings on salbutamol leaflets was a statement
indicating that “the safety and effectiveness in children under
the age of 4 years is not known.” Leaflets for anticholin-
ergics warned patients to exercise caution when operating
machinery or avoid driving due to the risk of dizziness or
blurred vision. The risk of systemic absorption from inhaled
anticholinergics is negligible [37], and these adverse effects
have been reported at an incidence of 3% or less (which in
most cases was similar to placebo) [37–41]. Furthermore, we
are unaware of any studies that have tested the effects of
inhaled anticholinergics on the ability to drive.
Even more alarming is the fact that several of the warn-
ings in the monographs are not consistent with current liter-
ature. For instance, all inhaled corticosteroids advised con-
sumers to avoid contact with individuals with measles or
chicken pox. While the risk of acquiring these illnesses is
increased in immunocompromised individuals taking oral
corticosteroids, this does not hold true for inhaled formula-
tions [42].
Several studies have indicated that negative information
may cause fear and provoke nonadherence to medications. In
one study in Australia, a third of consumers (35%, 242/691)
indicated they had concerns after reading the consumer
medication information [43], while in another study in
Copenhagen 32% of patients (35/111) stated that they had
stopped taking medication due to information about adverse
effects [44]. Recently, a qualitative study (𝑛 = 35) discovered
that the vast amount of side effects and drug interactions
reported in package leaflets of commonly prescribed med-
ications provoked fear and anxiety and caused patients to
stop their medication or alter their dosage regimen without
consulting a health care provider [10].
Studies have shown that confidence in drug therapy
could be low among patients with COPD [45], and medica-
tion underuse is the most prevalent type of nonadherence
with this illness [46]. Rather than emphasizing the (often
unfounded) risks, manufacturers should aim to encourage
adherence by describing the medication’s potential benefits.
Studies have demonstrated that patients want information
that is encouraging to read and how much a medicine will
assist them [10, 47]. We realize that drug manufacturers
have a duty to warn patients about foreseeable side effects
of medications but argue that the risk/benefit approach
should be used. Product warnings should only be included
in the leaflet, if it is reasonable and substantial enough to
warrant concern. Furthermore, manufacturers should make
an effort to consult with the ultimate stakeholder—the con-
sumer—prior to publishing the product monographs.
There are several limitations that should be acknowledged
with this study. First, only Canadian monographs written in
English were included in this evaluation. The patient medi-
cation information sections were retrieved from the Health
Canada Drug Product Database, so we were unable to assess
the layout of the information that is dispensed with the
devices. (Health Canada archives the monographs in pdf.
format, whereas the information provided with the devices
may be in the format of a booklet.) Readability and suitability
testswere used as surrogatemarkers to evaluate the likelihood
of patient comprehension of the materials, and a subjective
assessment was used to identify explicit warnings. A study
involving actual patients would be needed to directly assess
patient comprehension and to truly understand the per-
ceptions and consequences associated with the information
presented in the leaflets.
5. Conclusion
Consumer information intended to educate patients on
medications for COPD provides adequate instructions for
use; however, the main messages contained in the docu-
ments were negative, severe, and sometimes inappropriate.
In addition, improvements in the readability of the patient
information sections are possible since none of them were
rated at the appropriate reading level. Previous calls to
improve the design of educational materials have not been
acted upon.
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